A 2025 acquisition strengthened Pfizer's oncology position, involving Seagen, AstraZeneca, and Merck.
4 reports, 2 independent
Updated Aug 14
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A 2025 acquisition strengthened Pfizer's oncology position, involving Seagen, AstraZeneca, and Merck.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Seagen
American biotechnology company
Nothing else this week.
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
AstraZeneca
British-Swedish pharmaceutical company
-
Merck
public company in Indonesia
Related events
- Pfizer's performance is being analyzed in comparison to the broader market.
- Pfizer and Nexentis Technologies, both healthcare companies, are competing for investment, with Pfizer reporting higher revenue and earnings.
- Major pharmaceutical companies are competing for investment capital.
- AbbVie, Boehringer Ingelheim, and Pfizer were present at a clinical conference in Las Vegas.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
Coverage
Newest first; wire copies grouped- ZacksPFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last? With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined from their peak. Howev
- ZacksHere's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which account
- ReutersFactbox-Major deals involving U.S. drugmakers and biotechs over the past decade (Reuters) -Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to
- Unknown outlet